LON:BTG - BTG Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 834 +3.00 (+0.36 %) (As of 03/20/2019 04:00 PM ET)Previous CloseGBX 831Today's RangeGBX 831 - GBX 834.5052-Week RangeGBX 467.40 - GBX 853Volume1.49 million shsAverage Volume582,586 shsMarket Capitalization£3.23 billionP/E Ratio114.25Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. It operates through three segments: Interventional Medicine, Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications. This segment also provides interventional vascular products consisting of EKOS system, an ultrasonic catheter drug delivery device used in the treatment of blood clots; Varithena for the treatment of varicose veins; and PneumRx Coil for the treatment of emphysema, a debilitating lung disease. The Pharmaceuticals segment offers antidote products, such as CroFab for the treatment of crotalid snake envenomations; DigiFab for the treatment of digoxin toxicity; and Voraxaze for high-dose methotrexate toxicity. The Licensing segment provides Zytiga for treatment of prostate cancer; Two-Part Hip Cup; and Lemtrada. The company also manufactures and commercializes therapeutic ultrasound devices, and roxwood systems, as well as develops venous thrombus management devices. The company was formerly known as British Technology Group International plc and changed its name to BTG plc in March 1995. BTG plc was founded in 1948 and is headquartered in London, the United Kingdom. Receive BTG News and Ratings via Email Sign-up to receive the latest news and ratings for BTG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:BTG Previous Symbol CUSIPN/A CIKN/A Webwww.btgplc.com Phone+44-20-75750000Debt Debt-to-Equity RatioN/A Current Ratio2.91 Quick Ratio2.48Price-To-Earnings Trailing P/E Ratio114.25 Forward P/E Ratio18.53 P/E GrowthN/A Sales & Book Value Annual Sales£862.98 million Price / Sales3.74 Cash FlowGBX 73.83 per share Price / Cash Flow11.30 Book ValueGBX 345.70 per share Price / Book2.41Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares387,166,016Market Cap£3.23 billion Next Earnings Date5/13/2019 (Estimated) OptionableOptionable BTG (LON:BTG) Frequently Asked Questions What is BTG's stock symbol? BTG trades on the London Stock Exchange (LON) under the ticker symbol "BTG." How were BTG's earnings last quarter? BTG plc (LON:BTG) issued its quarterly earnings results on Tuesday, May, 15th. The company reported $32.90 EPS for the quarter, beating analysts' consensus estimates of $29.80 by $3.10. View BTG's Earnings History. When is BTG's next earnings date? BTG is scheduled to release their next quarterly earnings announcement on Monday, May 13th 2019. View Earnings Estimates for BTG. What price target have analysts set for BTG? 7 equities research analysts have issued 12-month target prices for BTG's shares. Their predictions range from GBX 490 to GBX 900. On average, they expect BTG's share price to reach GBX 732.50 in the next year. This suggests that the stock has a possible downside of 12.2%. View Analyst Price Targets for BTG. What is the consensus analysts' recommendation for BTG? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BTG in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for BTG. Has BTG been receiving favorable news coverage? News stories about BTG stock have been trending positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BTG earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. Who are some of BTG's key competitors? Some companies that are related to BTG include Cronos Group (CRON), MorphoSys (MOR), MorphoSys (MOR), Abcam (ABC), Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Senesco Technologies (ELOX) and Oxford BioMedica (OXB). What other stocks do shareholders of BTG own? Based on aggregate information from My MarketBeat watchlists, some companies that other BTG investors own include Editas Medicine (EDIT), Portola Pharmaceuticals (PTLA), Tahoe Resources (TAHO), Jagged Peak Energy (JAG), Advanced Micro Devices (AMD), Vectura Group (VEC), Barrick Gold (GOLD), First Majestic Silver (AG), McEwen Mining (MUX) and Yamana Gold (AUY). Who are BTG's key executives? BTG's management team includes the folowing people: Dr. Louise Makin MA, Ph.D.(Cantab), MBA, DBE, CEO & Exec. Director (Age 58)Mr. Duncan Kennedy A.C.A., B.Sc., CFO & DirectorDr. Peter Stratford, Chief Technical Officer & Head of Innovation (Age 52)Mr. Andy Burrows, VP of Corp. & Investor RelationsDr. Paul Mussenden, Gen. Counsel, Head of Strategic Affairs & Company Sec. How do I buy shares of BTG? Shares of BTG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is BTG's stock price today? One share of BTG stock can currently be purchased for approximately GBX 834. How big of a company is BTG? BTG has a market capitalization of £3.23 billion and generates £862.98 million in revenue each year. What is BTG's official website? The official website for BTG is https://www.btgplc.com/. How can I contact BTG? BTG's mailing address is 5 Fleet Place, LONDON, EC4M 7RD, United Kingdom. The company can be reached via phone at +44-20-75750000. MarketBeat Community Rating for BTG (LON BTG)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 567 (Vote Outperform)Underperform Votes: 381 (Vote Underperform)Total Votes: 948MarketBeat's community ratings are surveys of what our community members think about BTG and other stocks. Vote "Outperform" if you believe BTG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/20/2019 by MarketBeat.com StaffFeatured Article: What is a short straddle?